Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has accepted the company’s Biologics License Application for crovalimab, an investigational, novel anti-C5 recycling monoclonal antibody, for the treatment of paroxysmal nocturnal hemoglobinuria.
